Abstract
This study aims to investigate the disease-related knowledge of gout patients and doctors in south China and to identify the important targets of education for patients and doctors. A cross-section survey of 154 primary gout patients and 185 doctors who may see gout patients was conducted with a modified questionnaire with ten items of gout-related knowledge. The participants were considered to have gout-related knowledge if he or she correctly answered seven or more items. One hundred and forty-nine valid questionnaires from patients, 33 from rheumatology physicians, and 151 from non-rheumatology doctors were collected for statistical analysis. The mean correctly answered items of three groups were 6.6 ± 2.2, 9.6 ± 0.53, and 8.0 ± 1.4, with rate of being considered to have knowledge about gout 51.7, 100, and 90.1 %, respectively (P < 0.05). The correct answer rate for each particular item was over 80 % in the rheumatology physician group. Patients or non-rheumatology doctors knew the optimal serum uric acid (sUA) level (48.3 vs 55.6 %), the need to take lifelong urate-lowering drugs (29.5 vs 43.6 %), that allopurinol is a urate-lowering drug (55.7 vs 76.0 %), and how to prevent attacks induced by urate-lowering therapy (ULT) (60.4 vs 74.0 %). Logistic regression showed that higher education predicted which patients had gout-related knowledge. Both the gout patients and non-rheumatology doctors in south China had poor knowledge on ULT. Since many gout patients do not see rheumatologists, our data suggest that further education should focus on patients and non-rheumatologists and emphasize the use of urate-lowering drugs, treatment duration, the target sUA level, and prophylaxis against acute attacks.
Similar content being viewed by others
References
Fang W, Zeng X, Li M, Chen LX, Schumacher HJ, Zhang F (2006) The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol 33:2041–2049
Yu JW, Yang TG, Diao WX, Cai XQ, Li T, Zhong H et al (2010) Epidemiological study on hyperuricemia and gout in Foshan areas, Guangdong Province. Zhonghua Liu Xing Bing Xue Za Zhi 31:860–862
Zeng Q, Wang Q, Chen R, Xiao Z, Huang S, Xu J (2003) Primary gout in Shantou: a clinical and epidemiological study. Chin Med J (Engl) 116:66–69
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241
Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P et al (2006) EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312–1324
Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P et al (2006) EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301–1311
Chinese Rheumatology Association (2011) The diagnosis and treatment guideline of primary gout. Chin J Rheumatol 15:410–413
Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L et al (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71:1765–1770
Brook RA, Forsythe A, Smeeding JE, Lawrence EN (2010) Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 26:2813–2821
Mikuls TR (2007) Quality of care in gout: from measurement to improvement. Clin Exp Rheumatol 25:114–119
Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J et al (2009) Quality of life and disability in patients with treatment-failure gout. J Rheumatol 36:1041–1048
Taylor WJ, Colvine K, Gregory K, Collis J, McQueen FM, Dalbeth N (2008) The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. Clin Exp Rheumatol 26:620–626
Rees F, Jenkins W, Doherty M (2013) Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 72:826–830
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64:1431–1446
Zhang LY, Schumacher HR, Su HH, Dai L, Dinnella J, Baker JF et al (2011) Development and evaluation of a survey of gout patients concerning their knowledge about gout. J Clin Rheumatol 17:242–248
Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895–900
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266
Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y et al (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17:2937–2944
Spencer K, Carr A, Doherty M (2012) Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 71(9):1490–1495
Martini N, Bryant L, Te KL, Aho L, Chan R, Miao J et al (2012) Living with gout in New Zealand: an exploratory study into people's knowledge about the disease and its treatment. J Clin Rheumatol 18:125–129
Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T et al (1998) Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 431:13–18
Pascual E, Sivera F (2007) Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 66:1056–1058
Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47:356–360
Becker MA, Schumacher HJ, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450–2461
Edwards NL (2011) Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep 13:154–159
Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA (2010) Patients and providers view gout differently: a qualitative study. Chronic Illn 6:263–271
Singh JA, Hodges JS, Toscano JP, Asch SM (2007) Quality of care for gout in the US needs improvement. Arthritis Rheum 57:822–829
Weaver AL, Cheh MA, Kennison RH (2008) How PCP education can impact gout management: the gout essentials. J Clin Rheumatol 14:S42–S46
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, QH., Dai, L., Li, ZX. et al. Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China. Clin Rheumatol 32, 1633–1640 (2013). https://doi.org/10.1007/s10067-013-2333-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-013-2333-0